C
CareSync
Doctors, patients, linked digitally for better care: ChronicCareManagement for Medicare; 24/7 med records access, help w/ appts, more, for all types of patients
About CareSync
CareSync, founded in 2011 by Travis Bond and Jennifer Lux, operated as a healthcare technology firm specializing in chronic disease management. The company's creation was partly inspired by the experience of co-founder and COO Amy Gleason, a former nurse whose daughter was diagnosed with a rare autoimmune disease, highlighting the challenges of coordinating care among multiple providers. Travis Bond, a serial entrepreneur with a background in creating EMR systems, served as the CEO.
The company's core business was providing software and services to coordinate care for patients, particularly those with chronic conditions, among their families, caregivers, and various healthcare providers. CareSync targeted both individual consumers (B2C) and enterprise clients like hospitals and physician groups (B2B). Its business model was multi-tiered, offering a free, do-it-yourself mobile application for personal health record management, and premium subscription services. The free version provided tools for medication reminders, appointment planning, and health tracking. Premium models included services where CareSync staff would collect and digitize a patient's complete medical history, and provide a health assistant for scheduling and care coordination. For enterprise clients, CareSync offered a platform to facilitate the requirements for Medicare's Chronic Care Management (CCM) program, enabling providers to bill for care coordination services delivered between visits.
The platform aimed to solve the problem of fragmented medical records by creating a single, comprehensive, and shareable health timeline. This service collected a patient's records, organized the information into structured data, and made it accessible via a web and mobile app. At its peak, the company was valued at $46 million, having raised approximately $50 million in funding over several rounds from investors including Tullis Health Investors, Greycroft, and Merck Global Health Innovation Fund. However, the company faced significant financial instability, which was compounded by the departure of CEO Travis Bond. An attempt to sell the company to a syndicate of investors, including the founder of Shipt, fell through at the last minute in June 2018. This failed acquisition led to CareSync ceasing all operations on June 21, 2018, and laying off its 292 employees. In January 2019, Vatica Health acquired CareSync's technology assets.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Jan 2019 | $0 | — | Vatica Health | — |
| SERIES B✓Equity / VC | Aug 2017 | $27M | $106M | Greycroft Partners | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for CareSync is 310 monthly website visits. CareSync's team grew 100% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Tullis Health Investors
Greycroft Partners
Other known investors1 additional known investor
Vatica Health
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about CareSync on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CareSync’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







